FSD Pharma Inc. Files 6-K, Announces "Institutional" Approval
Ticker: QNTM · Form: 6-K · Filed: Jun 4, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Fsd Pharma Inc. (QNTM) |
| Form Type | 6-K |
| Filed Date | Jun 4, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, corporate-update
TL;DR
FSD Pharma filed a 6-K, got some kind of 'institutional' approval. Details light.
AI Summary
FSD Pharma Inc. filed a Form 6-K on June 4, 2024, to report its activities for the month of June 2024. The filing includes a press release announcing that FSD Pharma has received "Institutional" approval, though specific details regarding the nature or implications of this approval are not elaborated upon in the provided text. The company is incorporated in Canada and its principal executive offices are located in Toronto.
Why It Matters
This filing indicates a development for FSD Pharma, potentially related to its operations or regulatory standing, which could influence investor perception and future business strategies.
Risk Assessment
Risk Level: medium — The filing is a routine report, but the lack of specific details about the 'institutional' approval introduces uncertainty.
Key Players & Entities
- FSD Pharma Inc. (company) — Registrant
- Nathan Coyle (person) — Chief Financial Officer
- June 4, 2024 (date) — Filing Date
- Toronto, Ontario (location) — Principal Executive Office Location
FAQ
What specific type of "Institutional" approval did FSD Pharma Inc. receive?
The provided text of the 6-K filing mentions that FSD Pharma received "Institutional" approval, but it does not specify the nature or details of this approval.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed with the SEC on June 4, 2024.
Who signed the Form 6-K on behalf of FSD Pharma Inc.?
The Form 6-K was signed by Nathan Coyle, Chief Financial Officer, on behalf of FSD Pharma Inc.
What is FSD Pharma Inc.'s principal executive office address?
FSD Pharma Inc.'s principal executive office is located at 199 Bay St., Suite 4000, Toronto, Ontario M5L 1A9, Canada.
Does FSD Pharma Inc. file annual reports under Form 20-F or Form 40-F?
FSD Pharma Inc. indicated that it files annual reports under cover of Form 20-F.
Filing Stats: 146 words · 1 min read · ~1 pages · Grade level 9.7 · Accepted 2024-06-04 08:28:26
Filing Documents
- fsd_6k.htm (6-K) — 10KB
- fsd_ex991.htm (EX-99.1) — 18KB
- fsd_ex991img2.jpg (GRAPHIC) — 6KB
- 0001654954-24-007293.txt ( ) — 38KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. FSD Pharma Inc. (Registrant) Date: June 4, 2024 By: /s/ Nathan Coyle Nathan Coyle, Chief Financial Officer 2 EXHIBIT INDEX Exhibit Description 99.1 Press Release 3